Intellia Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Intellia Therapeutics, Inc. (NTLA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NTLA insiders buying or selling?
In the last 12 months, Intellia Therapeutics, Inc. insiders reported 1 open-market purchase ($1.4M) and 15 sales ($2.2M) — net selling of $760.8K. Since January 2018, Trabud has recorded 121 Form 4 filings for NTLA: 3 buys ($2.5M) and 118 sells ($272.0M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $1.4M by Fred E Cohen (Director) on Jan 7, 2026. SEC ↗
- The most recent open-market purchase was reported on Jan 7, 2026 (9 months ago).
Key Statistics (January 2018 – Oct 6, 2026)
Total Form 4 filings
121
SEC EDGAR
Insider filers
22
Insider buys (3)
$2.5M
Insider sells (118)
$272.0M
Insider sentiment
Net sellingNet insider flow of $269.4M in net selling since January 2018, and $760.8K in net selling over the last 12 months.
Recent NTLA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Dube Michael P | VP, Chief Accounting Officer | Sale | 1.9K | $12.43 | $23.2K | SEC ↗ |
| Aug 24, 2026 | John M Leonard | President and CEO | Sale | 22.7K | $12.65 | $286.8K | SEC ↗ |
| Jul 24, 2026 | Edward J Dulac III | EVP, Chief Financial Officer | Sale | 8.1K | $11.25 | $91.2K | SEC ↗ |
| Jul 6, 2026 | Dube Michael P | VP, Chief Accounting Officer | Sale | 2.6K | $16.78 | $44.3K | SEC ↗ |
| Jul 6, 2026 | Edward J Dulac III | EVP, Chief Financial Officer | Sale | 4.7K | $18.00 | $84.2K | SEC ↗ |
| Mar 3, 2026 | James Basta | EVP, General Counsel | Sale | 1.2K | $13.78 | $16.7K | SEC ↗ |
| Mar 3, 2026 | Eliana Clark | EVP, Chief Technical Officer | Sale | 607 | $13.78 | $8.4K | SEC ↗ |
| Jan 7, 2026 | John M Leonard | President and CEO | Sale | 34.1K | $9.21 | $314.5K | SEC ↗ |
| Jan 7, 2026 | Birgit C Schultes | EVP, Chief Scientific Officer | Sale | 8.5K | $9.21 | $78.4K | SEC ↗ |
| Jan 7, 2026 | James Basta | EVP, General Counsel | Sale | 10.4K | $9.21 | $95.8K | SEC ↗ |
| Jan 7, 2026 | Fred E Cohen | Director | Purchase | 150.0K | $9.35 | $1.4M | SEC ↗ |
| Jan 7, 2026 | David Lebwohl | EVP, Chief Medical Officer | Sale | 11.9K | $9.21 | $109.6K | SEC ↗ |
| Jan 7, 2026 | Eliana Clark | EVP, Chief Technical Officer | Sale | 9.5K | $9.21 | $87.6K | SEC ↗ |
| Jan 7, 2026 | Edward J Dulac III | EVP, Chief Financial Officer | Sale | 6.4K | $9.21 | $58.8K | SEC ↗ |
| Jan 7, 2026 | Dube Michael P | VP, Chief Accounting Officer | Sale | 3.0K | $9.21 | $27.5K | SEC ↗ |
| Dec 12, 2025 | John M Leonard | President and CEO | Sale | 88.1K | $9.49 | $836.4K | SEC ↗ |
| Oct 3, 2025 | Birgit C Schultes | EVP, Chief Scientific Officer | Sale | 31 | $17.38 | $538.78 | SEC ↗ |
| Oct 3, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sale | 1.9K | $17.38 | $32.5K | SEC ↗ |
| Aug 22, 2025 | William J Chase | Director | Purchase | 100.0K | $10.03 | $1.0M | SEC ↗ |
| Jul 25, 2025 | Edward J Dulac III | EVP, Chief Financial Officer | Sale | 7.5K | $14.02 | $104.6K | SEC ↗ |
| Jul 3, 2025 | Eliana Clark | EVP, Chief Technical Officer | Sale | 1.0K | $9.82 | $10.0K | SEC ↗ |
| Jul 3, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sale | 2.5K | $9.95 | $24.9K | SEC ↗ |
| Jul 2, 2025 | Jesse Goodman | Director | Sale | 3.1K | $9.40 | $29.1K | SEC ↗ |
| May 1, 2025 | Muna Bhanji | Director | Sale | 265 | $8.50 | $2.3K | SEC ↗ |
| Mar 4, 2025 | Eliana Clark | EVP, Chief Technical Officer | Sale | 679 | $8.99 | $6.1K | SEC ↗ |
Showing the 25 most recent of 121 Form 4 filings for Intellia Therapeutics, Inc..
Most active NTLA insiders
- John M Leonard24 filings
- Jose E Rivera13 filings
- Eliana Clark11 filings
- David Lebwohl10 filings
- FORMELA JEAN FRANCOIS10 filings
Ask anything about NTLA insider activity
Use Trabud's AI agent to query Intellia Therapeutics, Inc.'s Form 4 history in plain English — "Show me NTLA CEO purchases this year" or compare it against any other ticker.
Open the AI agentNTLA insider trading FAQ
Are Intellia Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Intellia Therapeutics, Inc. insiders reported 1 open-market purchase ($1.4M) and 15 sales ($2.2M) — net selling of $760.8K. Since January 2018, Trabud has recorded 121 Form 4 filings for NTLA: 3 buys ($2.5M) and 118 sells ($272.0M). Over the full record that is net selling of $269.4M.
How many insiders trade NTLA stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Intellia Therapeutics, Inc.. The most recent filing was accepted on Oct 6, 2026.
Where does Trabud get NTLA insider trading data?
All NTLA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.